Related Experiment Videos
[Thrombosis and lung cancer].
1Service d'Oncologie Médicale, Hôpital Avicenne, Bobigny, France. anne-marie.brechot@avc.ap-hop-paris.fr
Revue Des Maladies Respiratoires
|December 13, 2005
Summary
Venous thromboembolism (TE) is common in lung cancer patients. Low molecular weight heparin (LMWH) effectively treats and prevents TE, potentially improving survival through anti-neoplastic effects.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Context:
- Venous thromboembolism (TE) frequently affects lung cancer patients due to factors like venous stasis, tumor pro-coagulant factors, and treatment-related vascular injury.
- Low molecular weight heparin (LMWH) is the standard for acute TE treatment, replacing unfractionated heparin.
- Long-term LMWH is recommended for preventing recurrent TE, with prophylactic use in surgical or hospitalized patients.
Purpose:
- To review the role of low molecular weight heparin (LMWH) in managing venous thromboembolism (TE) in lung cancer patients.
- To highlight the anticoagulant and potential anti-neoplastic effects of heparin.
- To discuss prophylactic and therapeutic strategies for TE in this patient population.
Summary:
- Subcutaneous LMWH is preferred for acute TE treatment in lung cancer patients.
- Long-term LMWH is crucial for preventing TE recurrence.
- Heparin exhibits both anticoagulant and anti-neoplastic properties, contributing to improved overall survival.
Impact:
- Provides a comprehensive overview of LMWH use in lung cancer-associated TE.
- Emphasizes the dual benefits of LMWH, including survival advantages.
- Informs clinical practice regarding TE management and prophylaxis in oncology settings.